Loading
Everything OnCo dates to 2023: 719 entries, 176 papers, 132 papers listed on people's pages, 126 trials reported and 123 landmarks. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
719 dated entries in OnCo fall in 2023: 176 papers, 132 papers listed on people's pages, 126 trials reported, 123 landmarks, 66 approvals, 42 regulatory events, 20 financing rounds, 16 technologies, 13 guideline changes, 2 companies founded, 2 expected dates and 1 law or regulation.
Of those, 29 to the day, 27 to the month and 663 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
First-line extensive-stage small cell lung cancer with carboplatin and etoposide (CAPSTONE-1)
Advanced RCC after PD-1/PD-L1 and VEGF-TKI
Refractory mCRC with trifluridine/tipiracil (SUNLIGHT)
BRAF V600E metastatic NSCLC with encorafenib
First-line unresectable HCC
HR+/HER2- breast cancer with PIK3CA/AKT1/PTEN alteration, with fulvestrant
ALL and lymphoblastic lymphoma, in a multi-agent regimen, after hypersensitivity or silent inactivation to E. coli-derived asparaginase (adults and children from 1 month).
BRAF V600 mutation-positive advanced non-small-cell lung cancer, first line only. TA898, published 14 June 2023, recommends the combination only as first-line treatment of advanced...
First-line HR-positive, HER2-negative advanced breast cancer with an aromatase inhibitor (DAWNA-2)
EU brand Inaqovi
Decrease in febrile neutropenia in adults with non-myeloid malignancies on myelosuppressive chemotherapy
Maintenance to reduce relapse risk in high-risk neuroblastoma after ≥PR to prior therapy including anti-GD2
ESR1-mutant ER+/HER2- advanced breast cancer after ≥1 endocrine therapy
Relapsed/refractory myeloma after ≥4 lines (accelerated)
First-line advanced urothelial cancer with pembrolizumab
High-risk biochemical recurrence (EMBARK)
EU brand Tepkinly. Conditional marketing authorisation
Relapsed/refractory DLBCL or high-grade B-cell lymphoma after ≥2 lines (accelerated)
Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent
PSMA PET in prostate cancer
Refractory mCRC after fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF, and anti-EGFR if appropriate
Same
Relapsed/refractory DLBCL after ≥2 lines (accelerated)
Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping
Companion diagnostic for elacestrant (ESR1 mutation) in ER+/HER2- advanced breast cancer
Adult relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia
ALK-positive non-small-cell lung cancer after crizotinib; first line from 2024
Relapsed/refractory IDH1-mutated MDS
First-line anaemia in ESA-naive lower-risk MDS
Uveal melanoma with unresectable hepatic metastases via hepatic delivery system (Hepzato Kit)
Uveal melanoma with unresectable hepatic metastases affecting less than half the liver and no or limited extrahepatic disease
Intermediate/high-risk myelofibrosis with anaemia
With filgrastim, to mobilise haematopoietic stem cells for collection and autologous transplantation in multiple myeloma
Progressing desmoid tumours requiring systemic treatment
Neoadjuvant treatment of resectable non-small-cell lung cancer (4 cm or more, or node positive), with chemotherapy. TA876, published 22 March 2023 (CheckMate 816).
Adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy; NICE TA886 (10 May 2023) recommends within the marketing authorisation...
Adults and children aged 12 and over with haematologic malignancies undergoing umbilical cord blood transplantation after myeloablative conditioning, to reduce time to neutrophil r...
Relapsed or refractory marginal zone lymphoma
Previously treated MSI-high or dMMR endometrial, biliary, colorectal, gastric or small intestine cancer.
Mismatch repair deficient or MSI-high tumours: NICE TA914 (20 September 2023) covers previously treated endometrial, gastric, small intestine, biliary and colorectal cancer and doe...
Locally advanced unresectable or metastatic biliary tract cancer (gallbladder cancer included) with gemcitabine and cisplatin (KEYNOTE-966).
EU brand Pylclari (Curium)
Relapsed MCL after BTK inhibitor (accelerated, January); CLL/SLL after BTK and BCL-2 inhibitors (accelerated, December)
Untreated DLBCL, IPI ≥2, with R-CHP (Pola-R-CHP)
Newly diagnosed FLT3-ITD AML with 7+3, consolidation, and maintenance
Metastatic colorectal cancer after previous treatment or when those treatments are unsuitable.
ROS1+ locally advanced or metastatic NSCLC
Metastatic or recurrent locally advanced Merkel cell carcinoma
First-line unresectable hepatocellular carcinoma with camrelizumab (CARES-310)
HR+/HER2- metastatic breast cancer after endocrine therapy and ≥2 chemotherapies
Untreated RET fusion-positive advanced non-small-cell lung cancer. TA911, published 26 July 2023, recommends selpercatinib with managed access only, under a managed access agreemen...
First-line gastric or gastro-oesophageal junction adenocarcinoma with chemotherapy (ORIENT-16)
Same
EGFR exon 20 insertion NSCLC after platinum
HRR-mutant mCRPC with enzalutamide
Relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukaemia. DCGI market authorisation; first CAR-T approved in India
Relapsed/refractory myeloma after ≥4 lines (accelerated)
Companion diagnostic for cetuximab and panitumumab (KRAS/NRAS wild-type colorectal cancer) with tumour-profiling claims
Recurrent/metastatic nasopharyngeal carcinoma, first line with chemotherapy and later lines
Unresectable or metastatic HER2-low breast cancer after chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy (DESTINY-Breast04), hormone-re...
Refractory mCRC with bevacizumab
HER2+ RAS-wild-type mCRC with trastuzumab
HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer that has progressed after fluoropyrimidine, oxaliplatin and irinotecan, with trastuzumab.
Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping
Advanced renal cell carcinoma after a prior tyrosine kinase inhibitor, with everolimus (June 2023)
CLL/SLL, all lines (SEQUOIA, ALPINE)
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
CDSCO/DCGI market authorisation; the developer's page gives the year only
Novartis acquires rights after Clovis bankruptcy
Breakthrough Therapy designation, HER2+ biliary tract cancer
HER2+ RAS wild-type metastatic colorectal cancer with trastuzumab (MOUNTAINEER, accelerated)
CLL/SLL
ESR1-mutated ER+/HER2- advanced breast cancer after ≥1 endocrine therapy (EMERALD): first oral SERD
AstraZeneca licenses global rights from KYM Biosciences
HR+/HER2- metastatic breast cancer after endocrine therapy and ≥2 chemotherapies (TROPiCS-02)
Breakthrough Therapy designation, adjuvant melanoma
Breakthrough Therapy designation
Adjuvant indication broadened to remove Ki-67 requirement
PRIME designation
Accelerated approval with pembrolizumab, cisplatin-ineligible first line
MCL and MZL indications voluntarily withdrawn after confirmatory trials missed
Frontline Pola-R-CHP (POLARIX)
BLA submitted
Accelerated approval in DLBCL (EPCORE NHL-1)
With abiraterone in BRCA-mutated mCRPC (PROpel)
Accelerated approval, relapsed/refractory DLBCL after ≥2 lines
HRR-mutant mCRPC with enzalutamide (TALAPRO-2)
Conditional marketing authorisation
Frontline FLT3-ITD AML (QuANTUM-First)
dMMR primary advanced/recurrent endometrial cancer with chemotherapy (RUBY)
With trifluridine/tipiracil in refractory mCRC
SUNLIGHT combination
Niraparib + abiraterone (Akeega) for BRCA-mutated mCRPC (MAGNITUDE)
EMA approval
BRAF V600E NSCLC with binimetinib
Perioperative NSCLC (KEYNOTE-671)
First FDA approval for nasopharyngeal carcinoma
Breakthrough Therapy designation, anti-PD-1-failed melanoma
FRESCO-2
HR+/HER2- breast cancer with PIK3CA/AKT1/PTEN alteration, with fulvestrant (CAPItello-291): first AKT inhibitor
First systemic therapy for desmoid tumours (DeFi)
Complete response letter citing third-party manufacturing inspection findings
BLA submitted (HERTHENA-Lung01)
FDA declines full approval based on CodeBreaK 200; postmarketing dose study required
CLL/SLL accelerated approval
BMS licenses global rights ex-China from SystImmune (up to $8.4B)
First oral maintenance therapy; externally controlled evidence
Advanced RCC after PD-1/PD-L1 and VEGF-TKI (LITESPARK-005)
Full approval with pembrolizumab, all first-line advanced urothelial cancer (EV-302)
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
European Union, regulation.
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
1 row added, 1 row recategorised. Anchored to Annals of Oncology publication, January 2023.
1 row recategorised. Anchored to DREAMseq publication (JCO, January 2023).
2 rows added. Anchored to Annals of Oncology publication, 2023.
2 rows added. Anchored to FDA approvals of polatuzumab-R-CHP in the first line (April 2023, POLARIX), epcoritamab (May 2023) and glofitamab (June 2023).
1 row added. Anchored to FDA approvals of olaparib with abiraterone (May 2023, PROpel) and talazoparib with enzalutamide (June 2023, TALAPRO-2) for HRR-mutated castration-resistant...
1 row added. Anchored to FDA approval of quizartinib with induction and consolidation for FLT3-ITD AML, July 2023 (QuANTUM-First).
1 row added, 1 row removed. Anchored to FDA approvals of idecabtagene vicleucel (March 2021), ciltacabtagene autoleucel (February 2022), teclistamab (October 2022), talquetamab and...
1 row added, 1 row recategorised. Anchored to Annals of Oncology publication, 2023.
2 rows added. Anchored to FDA approvals of neoadjuvant nivolumab with chemotherapy (March 2022, CheckMate 816) and perioperative pembrolizumab (October 2023, KEYNOTE-671).
1 row recategorised, 1 row added. Anchored to FDA approvals of trifluridine/tipiracil with bevacizumab (August 2023, SUNLIGHT) and fruquintinib (November 2023, FRESCO-2).
2 rows added. Anchored to FDA approvals of elacestrant (January 2023) and capivasertib (November 2023).
1 row recategorised, 1 row added, 1 row removed. Anchored to FDA approval of zanubrutinib for CLL (January 2023, ALPINE and SEQUOIA) and pirtobrutinib after BTK and BCL-2 inhibitor...
1 row added. Anchored to FDA approval of belzutifan after immunotherapy and VEGF-TKI, December 2023 (LITESPARK-005).
The year reported on trial records, with the headline result the record gives.
Objective response 40 percent at the 10 mg dose and 32 percent at 100 mg in previously treated small-cell lung cancer; median progression-free survival 4.9 and 3.9 months.
Perioperative durvalumab with neoadjuvant platinum chemotherapy improved event-free survival (hazard ratio 0.69, 95 percent confidence interval 0.55 to 0.88 at the second interim a...
Five-year recurrence-free survival 79 percent with adjuvant mitotane against 75 percent with surveillance (hazard ratio 0.74, 95% CI 0.30 to 1.85); overall survival not significant...
Disease-free survival 85 per cent at 12 months and 84 per cent at 24 months with adjuvant nivolumab against 77 and 73 per cent with observation (hazard ratio 0.58, 95 per cent conf...
DFS HR 0.24.
Six-month progression-free survival 83% (10 of 12) in grade 1 and 33% (8 of 24) in grade 2 to 3 NF2-mutant meningioma; both cohorts met the trial's decision criterion for promising...
Ten-year axillary recurrence 1.82 percent after radiotherapy against 0.93 percent after clearance, with no difference in survival and lymphoedema halved (11.9 against 24.5 percent...
No patient had unacceptable toxicity and none was a feasibility failure over the first five induction cycles with dinutuximab and GM-CSF added.
Independently assessed disease-free survival 19.4 against 18.8 months (hazard ratio 0.88; p 0.18), primary endpoint not met; overall survival 41.8 against 37.7 months at five years...
3-year overall survival 77.1% vs 67.6%, adjusted HR 0.69 (0.51 to 0.94), one-sided p=0.0080.
Vaccine-induced T cells in 8 of 16 patients; median recurrence-free survival not reached in responders against 13.4 months in non-responders (p 0.003 at 18 months; p 0.007 at 3.2 y...
OS 32.1 vs 22.8 months (HR 0.68).
ctDNA detected in 27.3% by 12 months; 72% of ctDNA-positive patients had metastases on staging; 0 of 5 patients on pembrolizumab cleared ctDNA.
FOLFOXIRI plus bevacizumab better than a doublet for right-sided or RAS/BRAF-mutant disease; panitumumab no better than bevacizumab for left-sided wild-type disease.
5-year disease-free survival 63.6% (sublobar) vs 64.1% (lobectomy), non-inferior; 5-year overall survival 80.3% vs 78.9%.
Durvalumab added to chemoradiotherapy did not significantly improve progression-free survival in locally advanced cervical cancer.
Median overall survival 11.4 months with napabucasin plus nab-paclitaxel and gemcitabine against 11.7 months with chemotherapy alone (hazard ratio 1.07, 95 percent confidence inter...
OS 23.8 vs 15.2 months, HR 0.62.
PFS HR 0.26; OS HR 0.55.
OS 13.4 vs 14.9 months, HR 1.31 (95% CI 1.09-1.58); worse with nivolumab.
GALAXY: ctDNA+ post-op HR for recurrence ~10; ALTAIR: DFS endpoint not met.
Objective response 47% (37 of 78) in metastatic disease by independent central review at the primary report, median duration of response not reached; the current label reports 50%...
5-year PFS 81.3% (GIV), 69.8% (GV), 57.4% (RV), 50.7% (CIT).
Objective response 21 percent (8 of 38; 95 percent confidence interval 10 to 37); median progression-free survival 4.0 months; median overall survival 6.9 months; grade 3 treatment...
PFS HR 0.49.
More patients achieved transfusion independence with a haemoglobin rise on luspatercept than on epoetin alfa; first-line approval in August 2023.
PFS HR 1.03; OS HR 0.94, negative.
ORR 37.8% (5.4 mg/kg).
Confirmed durable responses to trastuzumab deruxtecan in a Western population after progression on trastuzumab.
Confirmed response rate 49.0% (5.4 mg/kg) vs 56.0% (6.4 mg/kg); interstitial lung disease 12.9% vs 28.0%.
Endometrial ORR 57.5% (84.6% in IHC 3+); cervical ORR 50%.
PFS HR 0.42 (dMMR, durvalumab); 0.57 (pMMR, durvalumab + olaparib).
PFS HR 0.63; interim OS HR 0.95.
MFS HR 0.42 (combination).
One-year overall survival 39 percent with immediate surgery against 78 percent with neoadjuvant gemcitabine plus capecitabine, 84 percent with FOLFIRINOX and 60 percent with chemor...
OS HR 0.47.
ORR 67% (RANO-HGG) and 51% (RAPNO-LGG) in arm 1; median DOR 16.6 months.
PFS HR 0.62; OS HR 0.77.
Residual or recurrent disease within two years 16.9 percent with six weeks of preoperative chemotherapy against 21.5 percent with postoperative chemotherapy alone (rate ratio 0.72...
OS 7.4 vs 4.8 months, HR 0.66.
ORR 63%, CR 33%; 3-year OS 60%.
Overall response rate 75%, (stringent) complete response 50% and very good partial response 25% in the first 20 patients; grade 1 to 2 cytokine release syndrome in 90%, no grade 3...
PFS 9.5 vs 7.4 months, HR 0.76; OS no benefit.
Confirmed ORR by independent central review 41.3% (33/80, 95% CI 30.4 to 52.8) in HER2 IHC 2+/3+ cohort; grade 3 treatment-related adverse events 18%; 53% of patients had gallbladd...
Interim RFS HR 0.72; benefit not sustained at update.
Imetelstat produced eight-week transfusion independence in significantly more patients than placebo; approved in June 2024.
PFS 15.0 vs 7.3 months, HR 0.43; OS 34.0 vs 27.0 months, HR 0.67.
OS 17.3 vs 16.1 months, HR 0.79; ORR 52% vs 29%.
PFS 27.7 vs 11.1 months, HR 0.39.
OS 11.5 vs 9.5 months (HR 0.70).
Residual cancer removed by guided margins in 27 of 357 patients; per-margin specificity 85.2% and sensitivity 49.3%; second surgery avoided in 9 of 62 patients with positive margin...
5-year OS 80% vs 72% (HR 0.60); PFS HR 0.65.
PFS 13.3 vs 4.4 months, HR 0.49.
EFS HR 0.58; OS HR 0.72.
OS HR 0.78 (all); CPS ≥10 OS 15.7 vs 11.8 months (HR 0.65).
OS 12.7 vs 10.9 months, HR 0.83.
PFS HR 0.70; 36-month OS 82.6% vs 74.8% (HR 0.67).
PFS HR 0.46.
PFS HR 0.28; 12-month PFS 86.8% vs 65.7%.
PFS HR 0.75; ORR 22.7% vs 3.5%; OS not significant.
1-year OS 43.4% vs 16.3%; median OS 10.1 vs 6.7 months; HR 0.545.
Weight gain over 5%: 60% vs 9%; appetite improvement 43% vs 13%.
5-year local recurrence 2.3% without radiotherapy in luminal A disease.
ORR 61%.
Complete response within 1 year: 43% vs 26%; complete response associated with better event-free survival.
PFS HR 0.70; OS HR 0.75.
Cancer detection 6.1 vs 5.1 per 1,000; screen-reading workload reduced 44.3% (interim).
ORR 65% (13 of 20), 4 complete responses; no FMT-related serious adverse events.
OS 16.46 vs 12.75 months (HR 0.67).
Momelotinib improved symptom response, transfusion independence and spleen response compared with danazol; approved in September 2023.
OS HR 0.84; PFS HR 0.69.
iDFS HR 0.75.
18-month disease-free survival 33.3 percent (perioperative) and 41.4 percent (adjuvant), both below the 55 percent target; median overall survival 25.5 against 16.7 months in the i...
EFS HR 0.48 vs external control.
Overall survival improved with nimotuzumab plus gemcitabine in KRAS wild-type disease.
PFS HR 0.30 (dMMR), 0.54 (pMMR).
OS 15.2 vs 12.3 months (HR 0.77); CPS ≥5: 18.4 vs 12.9 months (HR 0.66).
5-year DFS 86.6% vs 82.6% (HR 0.74); OS 90.1% vs 86.4% (HR 0.71).
PFS HR 0.42; 48-month PFS 84.3% vs 67.7%.
Response rate 75% (treatment-naive, n=59) and 46% (previously treated, n=39); FDA approval October 2023.
Pancreatic cancer cohort: objective response in 7 of 21 patients (33.3 percent); across the 57 evaluable non-lung, non-colorectal KRAS G12C tumours response 35.1 percent, median du...
Fewer severe complications and faster recovery with prehabilitation; surgery not delayed.
5-year disease-free survival 80.8% (FOLFOX, selective chemoradiation) vs 78.6% (chemoradiation), non-inferior; 9% of the FOLFOX arm received chemoradiation.
rPFS HR 0.41.
OS 44.6 vs 28.2 months overall (HR 0.69); dMMR PFS HR 0.28.
2-year OS non-inferior (HR 1.14); ~one-third avoided surgery.
One radiologist plus AI detected 261 screen-detected cancers vs 250 for two radiologists (relative proportion 1.04, 95% CI 1.00 to 1.09), meeting non-inferiority; AI alone 246 and...
Five-year distant disease-free survival 98.0 percent without axillary surgery against 97.7 percent with sentinel node biopsy (hazard ratio 0.84, non-inferiority p=0.02).
SPOTLIGHT OS 18.2 vs 15.5 months; GLOW OS 14.4 vs 12.2 months.
OS 10.8 vs 7.5 months, HR 0.61.
2-year PFS 92% vs 83%, HR 0.45.
ORR 47% vs 11%; median PFS 20.1 vs 7.4 months, HR 0.31.
rPFS HR 0.63 (ITT); OS HR 0.80 (ITT), 0.62 (HRR-mutant).
OS 12.1 vs 7.8 months, HR 0.64 (cohort 1).
Copy-number heterogeneity predicted recurrence or death with a hazard ratio of 4.9; 8 percent of adenocarcinomas in people with a smoking history carried no tobacco signature; in t...
CR/CRi 18-20%; ORR 47%; uMRD blood 64%.
Median imaging-based progression-free survival 11.2 against 6.4 months in the BRCA subgroup (hazard ratio 0.50, 95 percent confidence interval 0.36 to 0.69) and 10.2 against 6.4 mo...
PFS HR 0.63; OS HR 1.01.
PFS HR 0.75; OS HR 0.94.
ORR 43.6% in EGFR-mutant disease.
The publication year on key paper records.
Pramesh CS, Sengar M, Patankar S, et al. Bulletin of the World Health Organization.
Xu B, Ma F, Wang T, et al. International journal of cancer.
Hogan LE, Brown PA, Ji L, et al. Journal of Clinical Oncology.
Johnston SRD, Toi M, O'Shaughnessy J, et al. The Lancet Oncology.
Attard G, Murphy L, Clarke NW, et al. The Lancet Oncology.
Cheng J, Novati G, Pan J, et al. Science.
Terzolo M, Fassnacht M, Perotti P, et al. The Lancet Diabetes and Endocrinology.
Francis PA, Fleming GF, Láng I, et al. Journal of Clinical Oncology.
Tolaney SM, Tarantino P, Graham N, et al. The Lancet Oncology.
Brastianos PK, Twohy EL, Gerstner ER, et al. Journal of Clinical Oncology.
Zhou C, Tang KJ, Cho BC, et al. New England Journal of Medicine.
Cho BC, Kim DW, Spira AI, et al. Nature Medicine.
Dembrower K, Crippa A, Colón E, et al. The Lancet Digital Health.
Mok TSK, Lopes G, Cho BC, et al. Annals of Oncology.
Garassino MC, Gadgeel S, Novello S, et al. JTO Clinical and Research Reports.
Chen AP, Sharon E, O'Sullivan-Coyne G, et al. New England Journal of Medicine.
Issa GC, Aldoss I, DiPersio J, et al. Nature.
Guo X, Chang M, Wang Y, et al. International journal of biological sciences.
Vogel A, Bridgewater J, Edeline J, et al. Annals of Oncology.
van der Sluis IM, de Lorenzo P, Kotecha RS, et al. New England Journal of Medicine.
Kunkler IH, Williams LJ, Jack WJL, et al. New England Journal of Medicine.
Rushbrook SM, Kendall TJ, Zen Y, et al. Gut.
Zhou C, Chen G, Huang Y, et al. Journal of Thoracic Oncology.
Qin S, Chan SL, Gu S, et al. The Lancet.
Krämer A, Bochtler T, Pauli C, et al. Annals of Oncology.
Turner NC, Oliveira M, Howell SJ, et al. New England Journal of Medicine.
San-Miguel J, Dhakal B, Yong K, et al. New England Journal of Medicine.
Kim DW, Kim SW, Camidge DR, et al. Journal of Thoracic Oncology.
Kirkwood JM, Del Vecchio M, Weber J, et al. Nature Medicine.
Mackensen A, Haanen JBAG, Koenecke C, et al. Nature Medicine.
Strickler JH, Satake H, George TJ, et al. New England Journal of Medicine.
de Langen AJ, Johnson ML, Mazieres J, et al. The Lancet.
Fakih MG, Salvatore L, Esaki T, et al. New England Journal of Medicine.
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. CA: A Cancer Journal for Clinicians.
Aix SP, Ciuleanu TE, Navarro A, et al. The Lancet. Respiratory medicine.
Platzbecker U, Della Porta MG, Santini V, et al. The Lancet.
Sigurjonsdottir G, De Marchi T, Ehinger A, et al. Breast Cancer Research.
Barchuk A, Tursun-Zade R, Nazarova E, et al. BMC cancer.
Stecklein SR, Kimler BF, Yoder R, et al. npj Breast Cancer.
Li Z, Song Z, Zhao Y, et al. Journal of Thoracic Oncology.
Bouffet E, Hansford JR, Garrè ML, et al. New England Journal of Medicine.
Hargrave DR, Terashima K, Hara J, et al. Journal of Clinical Oncology.
Watson JL, Juergens D, Bennett NR, et al. Nature.
Ahn MJ, Cho BC, Felip E, et al. New England Journal of Medicine.
Goto K, Goto Y, Kubo T, et al. Journal of Clinical Oncology.
Asherie N, Kfir-Erenfeld S, Avni B, et al. Haematologica.
Petersenn S, Fleseriu M, Casanueva FF, et al. Nature reviews. Endocrinology.
Atkins MB, Lee SJ, Chmielowski B, et al. Journal of Clinical Oncology.
Ahn MJ, Bondarenko I, Kalinka E, et al. Journal of Thoracic Oncology.
Brouwer OR, Albersen M, Parnham A, et al. European Urology.
Molenaar CJL, Minnella EM, Coca-Martinez M, et al. JAMA surgery.
Badwe RA, Parmar V, Nair N, et al. Journal of Clinical Oncology.
Clingan P, Ladwa R, Brungs D, et al. Journal for ImmunoTherapy of Cancer.
Solomon BJ, Bauer TM, Mok TSK, et al. The Lancet. Respiratory medicine.
Matulonis UA, Lorusso D, Oaknin A, et al. Journal of Clinical Oncology.
Freedland SJ, de Almeida Luz M, De Giorgi U, et al. New England Journal of Medicine.
Thieblemont C, Phillips T, Ghesquieres H, et al. Journal of Clinical Oncology.
Frampton JE. Drugs.
Keam SJ. Molecular diagnosis & therapy.
Rodolakis A, Scambia G, Planchamp F, et al. International journal of gynecological cancer.
Ghaneh P, Palmer D, Cicconi S, et al. The Lancet Gastroenterology and Hepatology.
Routy B, Lenehan JG, Miller WH, et al. Nature Medicine.
Vogel A, Segatto O, Stenzinger A, et al. Annual review of medicine.
Cole CB, Morelli MP, Fantini M, et al. Journal of experimental & clinical cancer research.
Özgüroğlu M, Kilickap S, Sezer A, et al. The Lancet Oncology.
Nishio M, Ohe Y, Ikeda S, et al. International journal of clinical oncology.
de Castro G, Kudaba I, Wu YL, et al. Journal of Clinical Oncology.
Dasari A, Lonardi S, Garcia-Carbonero R, et al. The Lancet.
Kotani D, Oki E, Nakamura Y, et al. Nature Medicine.
Shah MA, Shitara K, Ajani JA, et al. Nature Medicine.
Yu Y, Zhou J, Li X, et al. EClinicalMedicine.
Yu HA, Goto Y, Hayashi H, et al. Journal of Clinical Oncology.
Wolff AC, Somerfield MR, Dowsett M, et al. Journal of Clinical Oncology.
Chamie K, Chang SS, Kramolowsky E, et al. NEJM Evidence.
Qin S, Chen M, Cheng AL, et al. The Lancet.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. New England Journal of Medicine.
Franklin JM, Wu Z, Guan KL. Nature Reviews Cancer.
Carlson LE, Ismaila N, Addington EL, et al. Journal of Clinical Oncology.
Zhou C, Wang Z, Sun M, et al. Nature Cancer.
Partridge AH, Niman SM, Ruggeri M, et al. New England Journal of Medicine.
Smith BL, Hunt KK, Carr D, et al. NEJM Evidence.
Japanese Gastric Cancer Association. Gastric cancer.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. New England Journal of Medicine.
Chu Q, Perrone F, Greillier L, et al. The Lancet.
Janjigian YY, Kawazoe A, Bai Y, et al. The Lancet.
Rha SY, Oh DY, Yañez P, et al. The Lancet Oncology.
Kelley RK, Ueno M, Yoo C, et al. The Lancet.
Bekaii-Saab TS, Yaeger R, Spira AI, et al. Journal of Clinical Oncology.
Yaeger R, Weiss J, Pelster MS, et al. New England Journal of Medicine.
Zhou C, Solomon B, Loong HH, et al. New England Journal of Medicine.
Hadoux J, Elisei R, Brose MS, et al. New England Journal of Medicine.
Altorki N, Wang X, Kozono D, et al. New England Journal of Medicine.
Patil VM, Noronha V, Menon N, et al. Journal of Clinical Oncology.
Hill W, Lim EL, Weeden CE, et al. Nature.
Authors not listed. Journal not given.
Kishan AU, Ma TM, Lamb JM, et al. JAMA Oncology.
Lesokhin AM, Tomasson MH, Arnulf B, et al. Nature Medicine.
Lång K, Josefsson V, Larsson AM, et al. Lancet Oncology.
Hassan R, Butler M, O'Cearbhaill RE, et al. Nature Medicine.
Gerstberger S, Jiang Q, Ganesh K. Cell.
Cervantes A, Adam R, Roselló S, et al. Annals of Oncology.
Moore KN, Angelergues A, Konecny GE, et al. New England Journal of Medicine.
Verstovsek S, Gerds AT, Vannucchi AM, et al. The Lancet.
Engstrom LD, Aranda R, Waters L, et al. Cancer Discovery.
Wainberg ZA, Melisi D, Macarulla T, et al. The Lancet.
Patel SP, Othus M, Chen Y, et al. New England Journal of Medicine.
Qin S, Li J, Bai Y, et al. Journal of Clinical Oncology.
Chi KN, Rathkopf D, Smith MR, et al. Journal of Clinical Oncology.
Gounder M, Ratan R, Alcindor T, et al. New England Journal of Medicine.
Eskander RN, Sill MW, Beffa L, et al. New England Journal of Medicine.
Ring A, Kilburn LS, Pearson A, et al. Clinical Cancer Research.
Saad F, Clarke NW, Oya M, et al. The Lancet Oncology.
Whelan TJ, Smith S, Parpia S, et al. New England Journal of Medicine.
Planchard D, Jänne PA, Cheng Y, et al. New England Journal of Medicine.
Mileshkin LR, Moore KN, Barnes EH, et al. The Lancet Oncology.
Jiménez-Gaona Y, Vivanco-Galván O, Morales-Larreategui G, Cabrera-Bejarano A, Lakshminarayanan V. Nursing Reports.
Long GV, Stephen Hodi F, Lipson EJ, et al. NEJM Evidence.
Felip E, Altorki N, Zhou C, et al. Annals of Oncology.
Ascierto PA, Stroyakovskiy D, Gogas H, et al. The Lancet Oncology.
Rugo HS, Bardia A, Marmé F, et al. The Lancet.
Conroy T, Pfeiffer P, Vilgrain V, et al. Annals of Oncology.
Watanabe J, Muro K, Shitara K, et al. JAMA.
Schrag D, Beer TM, McDonnell CH, et al. The Lancet.
Blay JY, Chevret S, Le Cesne A, et al. The Lancet Oncology.
Novello S, Kowalski DM, Luft A, et al. Journal of Clinical Oncology.
Heymach JV, Harpole D, Mitsudomi T, et al. New England Journal of Medicine.
Provencio M, Nadal E, Gonzalez-Larriba JL, et al. New England Journal of Medicine.
Wakelee H, Liberman M, Kato T, et al. New England Journal of Medicine.
Riely GJ, Smit EF, Ahn MJ, et al. Journal of Clinical Oncology.
de Vries EGE, Rüschoff J, Lolkema M, et al. Cancer medicine.
Mi JQ, Zhao W, Jing H, et al. Journal of Clinical Oncology.
Gotlib J, Castells M, Elberink HO, et al. NEJM Evidence.
Morton D, Seymour M, Magill L, et al. Journal of Clinical Oncology.
Karschnia P, Young JS, Dono A, et al. Neuro-Oncology.
Schrag D, Shi Q, Weiser MR, et al. New England Journal of Medicine.
Hamdy FC, Donovan JL, Lane JA, et al. New England Journal of Medicine.
Mascia AE, Daugherty EC, Zhang Y, et al. JAMA Oncology.
Erba HP, Montesinos P, Kim HJ, et al. The Lancet.
Omuro A, Brandes AA, Carpentier AF, et al. Neuro-Oncology.
Sandhya L, Devi Sreenivasan N, Goenka L, et al. Journal of Clinical Oncology.
Chesney JA, Ribas A, Long GV, et al. Journal of Clinical Oncology.
Wen PY, van den Bent M, Youssef G, et al. Journal of Clinical Oncology.
Carson JL, Stanworth SJ, Guyatt G, et al. JAMA.
Sonabend AM, Gould A, Amidei C, et al. The Lancet Oncology.
Turner NC, Swift C, Jenkins B, et al. Annals of Oncology.
Bradley RK, Anczuków O. Nature Reviews Cancer.
Rojas LA, Sethna Z, Soares KC, et al. Nature.
Mirza MR, Chase DM, Slomovitz BM, et al. New England Journal of Medicine.
Harrison CN, Nangalia J, Boucher R, et al. Journal of Clinical Oncology.
Karius A, Schweizer C, Strnad V, et al. Radiotherapy and Oncology.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. New England Journal of Medicine.
Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Nature Reviews Clinical Oncology.
Siegel RL, Miller KD, Wagle NS, Jemal A. CA: A Cancer Journal for Clinicians.
Xu J, Jiang H, Pan Y, et al. JAMA.
Shitara K, Lordick F, Bang YJ, et al. The Lancet.
Mikhael PG, Wohlwend J, Yala A, et al. Journal of Clinical Oncology.
Agarwal N, Azad AA, Carles J, et al. The Lancet.
Lanzi C, Arrighetti N, Pasquali S, et al. Biochemical pharmacology.
Mazieres J, Paik PK, Garassino MC, et al. JAMA Oncology.
Ali SZ, Baloch ZW, Cochand-Priollet B, et al. Thyroid.
de Visser KE, Joyce JA. Cancer Cell.
O'Dwyer PJ, Gray RJ, Flaherty KT, et al. Nature Medicine.
Hassel JC, Piperno-Neumann S, Rutkowski P, et al. New England Journal of Medicine.
Mai HQ, Chen QY, Chen D, et al. JAMA.
Frankell AM, Dietzen M, Al Bakir M, et al. (TRACERx Consortium). Nature.
Theodoris CV, Xiao L, Chopra A, et al. Nature.
Hurvitz SA, Hegg R, Chung WP, et al. The Lancet.
Prager GW, Taieb J, Fakih M, et al. New England Journal of Medicine.
Fizazi K, Piulats JM, Reaume MN, et al. New England Journal of Medicine.
Nakamura Y, Mizuno N, Sunakawa Y, et al. Journal of Clinical Oncology.
Strickler JH, Cercek A, Siena S, et al. The Lancet Oncology.
Curigliano G, Burstein HJ, Gnant M, et al. Annals of Oncology.
Key NS, Khorana AA, Kuderer NM, et al. Journal of Clinical Oncology.
Harding JJ, Fan J, Oh DY, et al. The Lancet Oncology.
Brown JR, Eichhorst B, Hillmen P, et al. New England Journal of Medicine.
Cowan AJ, Pont MJ, Sather BD, et al. The Lancet Oncology.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)
Adrenocortical carcinoma
Merkel cell carcinoma. 179 patients randomised 2 to 1 to a year of nivolumab or observation; disease-free survival 84 against 73 per cent at 24 months, hazard ratio 0.58 with a con...
Lung cancer (all types). PM2.5 was shown to promote rather than initiate EGFR-driven lung cancer, with oncogenic EGFR mutations in 18 percent of histologically normal lungs; FLAURA...
HER2-low and HER2-ultralow metastatic breast cancer
Alveolar soft part sarcoma
Resectable pancreatic ductal adenocarcinoma
Systemic mastocytosis. PIONEER; FDA approval May 2023, the first therapy for the indolent form.
Non-Hodgkin lymphoma (all types). Glofitamab and epcoritamab, off-the-shelf CD20 x CD3 antibodies, approved for relapsed large B-cell lymphoma.
Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)
Essential thrombocythaemia (ET). Merck starts the Shorespan-007 trial against hydroxyurea in high-risk ET.
Triple-negative breast cancer (TNBC). UK trial, 161 women under surveillance; 27 percent ctDNA-positive by a year, 72 percent of them already metastatic on staging; none of five gi...
Multiple myeloma
Stage IIB and IIC melanoma
Chondrosarcoma
Chronic lymphocytic leukaemia, first treatment
KRAS G12C-mutant pancreatic ductal adenocarcinoma
KRAS G12C-mutant non-small-cell lung cancer
Lower-risk myelodysplastic syndromes
Renal cell carcinoma
Triple-negative breast cancer (TNBC). Stecklein's 80-patient registry: ctDNA positive in a third of residual-disease patients, rising with RCB class, with three-year event-free sur...
Paediatric high-grade glioma (excluding diffuse midline glioma). Hargrave and colleagues (JCO) report durable responses in the paediatric cohort.
HER2-mutant non-small-cell lung cancer
Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)
Mismatch-repair-deficient endometrial cancer
Pancreatic neuroendocrine tumours
Penile cancer. First joint European and American guideline for penile cancer.
Localised penile cancer (organ-confined, node-negative)
Node-positive and metastatic penile cancer
High-risk neuroblastoma
HR-positive metastatic breast cancer after CDK4/6 inhibitors
HR-positive / HER2-negative breast cancer
Biochemical recurrence of prostate cancer
Urethral cancer. Applied by extrapolation to urothelial-type urethral carcinoma.
Lung cancer (all types). Announced on 26 June 2023 at a cost of £270 million a year once fully implemented, expected to deliver almost one million scans and find as many as 9,000 c...
Vaginal cancer
Cancer of unknown primary, favourable subsets
Cancer of unknown primary (CUP)
Borderline resectable pancreatic ductal adenocarcinoma
Bladder & urothelial cancer
Muscle-invasive and advanced bladder cancer
Bladder & urothelial cancer
HER2-amplified colorectal cancer
EGFR-mutated non-small-cell lung cancer
Colorectal cancer. Six weeks of oxaliplatin and fluoropyrimidine before surgery, then 18 weeks after, left fewer patients with residual or recurrent disease at two years than 24 we...
Neuroblastoma (paediatric)
Neuroblastoma (paediatric)
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma
HER2-positive breast cancer with brain metastases
Gallbladder cancer. Zanidatamab response rate 41.3 percent in HER2-positive disease after chemotherapy.
Myelodysplastic syndromes / neoplasms (MDS). Magrolimab (ENHANCE) and sabatolimab (STIMULUS-MDS2) add nothing to azacitidine; VERONA (venetoclax) negative in 2024.
Early hepatocellular carcinoma (BCLC 0 and A)
Mesothelioma
Astrocytoma, IDH-mutant (grades 2 to 4). Mellinghoff and colleagues (NEJM): median progression-free survival 27.7 versus 11.1 months.
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
Glioma & glioblastoma
Recurrent or metastatic cervical cancer
Locally advanced cervical cancer
Relapsed or refractory multiple myeloma
Resectable stage I to III non-small-cell lung cancer
PD-L1-high gastric cancer
Stage III melanoma (after surgery)
Intrahepatic cholangiocarcinoma
Biliary tract cancer (cholangiocarcinoma)
Gallbladder cancer
Cervical cancer. Four practice-changing phase 3 results presented at ESMO 2023.
Locally advanced cervical cancer
KRAS G12C-mutant colorectal cancer
RET fusion-positive non-small-cell lung cancer
Thyroid cancer
Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4). Hadoux and colleagues, NEJM.
Medullary thyroid cancer
Buccal mucosa and gingivobuccal cancer (oral cancer in India)
Higher-risk myelodysplastic syndromes
Secondary and therapy-related acute myeloid leukaemia
Polycythaemia vera (PV). Ruxolitinib beat best available therapy after hydroxyurea failure, and complete responders had better event-free survival.
Non-small-cell lung cancer
Platinum-resistant ovarian cancer
Primary myelofibrosis
Myeloproliferative neoplasms (PV, ET, myelofibrosis). MOMENTUM: symptom, spleen and transfusion-independence benefit versus danazol.
Pancreatic ductal adenocarcinoma
Metastatic pancreatic ductal adenocarcinoma
High-risk early HR-positive breast cancer
Microsatellite-unstable (MSI-high) gastric cancer
Desmoid tumour. DeFi phase 3 (NEJM 2023); FDA approval 27 November 2023, the first for desmoid tumours.
Sarcomas (soft tissue, bone, GIST)
KRAS wild-type pancreatic ductal adenocarcinoma
Prostate cancer
Prostate cancer. TRITON3 randomised 405 men and found imaging-based progression-free survival of 11.2 against 6.4 months in the BRCA subgroup, and a hazard ratio of 0.95 in the ATM...
Uveal melanoma
BRAF V600E-mutant non-small-cell lung cancer
Indolent and smouldering systemic mastocytosis
Richter transformation of chronic lymphocytic leukaemia
Relapsed or refractory chronic lymphocytic leukaemia
Mantle cell lymphoma
Rectal cancer
Localised prostate cancer, very low and low risk
Metastatic castration-resistant prostate cancer
FLT3-mutated acute myeloid leukaemia
Acute myeloid leukaemia. QuANTUM-First OS 31.9 vs 15.1 months, including patients to age 75.
Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei
Merkel cell carcinoma
Mismatch-repair-deficient endometrial cancer
Advanced or recurrent endometrial cancer
Endometrial cancer. Three trials in one year; dostarlimab approved for dMMR (July 2023).
Endometrial cancer
Oesophageal cancer
Ovarian cancer. First-line maintenance benefit confirmed while later-line PARP use retreats after OS imbalances (ARIEL4, SOLO3).
Platinum-sensitive ovarian cancer
Gastric & gastro-oesophageal junction cancer
Claudin 18.2-positive gastric cancer
Uterine carcinosarcoma
Colorectal cancer
Hodgkin lymphoma
Paediatric low-grade glioma. Higher response rate and longer progression-free survival than carboplatin-vincristine in BRAF V600E pLGG (NEJM); FDA approval in March 2023.
Recurrent or metastatic head and neck squamous cell carcinoma
Recurrent and metastatic nasopharyngeal carcinoma
Head and neck squamous cell carcinoma
Nasopharyngeal carcinoma
ROS1-positive non-small-cell lung cancer
Non-small-cell lung cancer. In the trials of pembrolizumab with chemotherapy, continuous tissue mutational burden predicts nothing in either histology, and neither do STK11, KEAP1...
Chronic lymphocytic leukaemia. First BTKi to beat ibrutinib head to head; first non-covalent BTKi in CLL (December).
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Schiphol
South San Francisco, CA
The funding rounds on company records, each with the source that states the figure.
$110m. Led by venBio Partners; the company's launch release reports USD 142 million in combined Series A and B financing
$48m. Round name not given in the release (listed as Series A1 extension on the company news page); existing investors plus new investor Labcorp; cumulative funding $108 million.
$90m
$281m. 18,750,000 shares at $15.00; Nasdaq CRGX
$45m. Led by OMERS Growth Equity
Deal terms not disclosed; founding investor Heidelberg Pharma expected about USD 7 million for its stake plus up to USD 5 million in milestones
$165m. 165 million US dollar private placement closed concurrently with the reverse merger into Imara (Nasdaq: ELVN) on 23 February 2023
$5m. Series A3
$392m. Quest 10-K: all-cash transaction for $392 million net of cash acquired, comprising $304 million cash and contingent consideration initially estimated at $88 million; up to $...
$55m. Led by 83North, September 2023; cumulative funding over $100 million.
$70m. Led by Nextech Invest with participation from Bristol Myers Squibb and existing investors
Agreement announced 18 October 2023; terms not disclosed
$175m
$320m. Initial payment of $200 million on completion (16 January 2023) plus up to $120 million in contingent milestone and non-contingent consideration; total up to $320 million
$210m. Described by STAT as a private financing round led by GV with SR One and Atlas Venture; no series letter given
$14m. Led by DCVC
$25m. Company page dated January 2023; investors not named on the page
$1.4bn. Cash tender offer at USD 12.50 per share, an aggregate of approximately USD 1.4 billion, under a merger agreement dated 2 October 2023; completion reported in an 8-K filed...
Completed in the first quarter of 2023; Gilead reported acquired IPR&D of $481 million for the quarter driven primarily by Tmunity plus Arcellx and Nurix payments, so the Tmunity p...
$70m. Initial closing of approximately $70 million with investors including Quest Diagnostics, announced 20 November 2023.
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Cancer Res
New England Journal of Medicine
Lancet Oncology
NEJM
JCO Glob Oncol
Immunity
Lancet Digital Health
NEJM Evidence
Lancet Oncology
Journal of Cancer Education
JAMA Oncology
Lancet
Nature Communications
NEJM
Supportive Care in Cancer
Journal of Clinical Oncology
Biomedicines
Lancet
eLife
Lancet
The Lancet Regional Health - Western Pacific
Cancer Med
NEJM
JACC. Cardiovascular imaging
South Asian Journal of Cancer
Journal of Medical Imaging and Radiation Oncology
Lancet Oncology
Nature Medicine
Journal of Cancer Policy
BMJ Open
Journal of Experimental & Clinical Cancer Research
Acta Oncologica
NEJM
JAMA
Cancer Discovery
Lancet
Neuro-Oncology
JCO
European Urology
International Journal of Gynecological Cancer
Supportive Care in Cancer
JAMA Network Open
Nature Cancer
Nature Medicine
New England Journal of Medicine
Haematologica
Nature
Journal of Clinical Oncology
NEJM
Lancet
NEJM
Cell Death & Differentiation
Frontiers in Oncology
Cell Reports
JAMA Pediatrics
ecancermedicalscience
European Journal of Nuclear Medicine and Molecular Imaging
Journal of Clinical Oncology
Lancet Gastroenterology and Hepatology
International Journal of Oncology
Stem Cell Reports
JCO
Journal of Clinical Oncology
Nature Medicine
Journal of Clinical Oncology
The Lancet Diabetes and Endocrinology
New England Journal of Medicine
NEJM
Nature Medicine
The Lancet Oncology
Br J Surg
Nature Communications
Lancet
The Lancet
NPJ Precision Oncology
Annals of Surgery
Journal of Clinical Oncology
Cancer Discovery
J Cancer Res Clin Oncol
Nature Reviews Clinical Oncology
J Clin Oncol
NEJM
Nature
Annals of Oncology
JCO
Journal of Clinical Oncology
Annals of Oncology
NEJM
Cold Spring Harbor Perspectives in Medicine
Lancet Oncology
Journal of Clinical Oncology
JAMA
Journal of Clinical Oncology
Annals of Oncology
NEJM
Lancet Oncology
Lancet Oncol
The Lancet Global Health
Nature
Journal of Clinical Oncology
Lancet Haematology
eLife
NEJM
Nature Medicine
Journal of Clinical Oncology
BMJ
Cancer Treatment and Research Communications
The Oncologist
BMJ Open
Gynecologic Oncology
NEJM
New England Journal of Medicine
JCO
Critical Reviews in Oncology/Hematology
Cell Research
New England Journal of Medicine
JAMA Oncology
NEJM
Cancer Medicine
Jpn J Clin Oncol
Nature
Nature
Cancer Cell
The Lancet Regional Health - Western Pacific
Journal of Clinical Oncology
British Journal of Haematology
NEJM
Nature
NEJM
Nature Medicine
Lancet
Lancet
Dates a source states for something still to come: roadmap watch items, the readout calendar, company catalysts, and registry primary completion dates.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.